{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:28:56Z","timestamp":1788456536912,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To systematically summarize the landscape and characteristics of all approved new anticancer drugs for the last 10 years in China and the United States (US) to further inform the trend, current state, and existing gap in the availability and affordability of cancer medicine between the two countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Mainly based on the Pharmcube database, a list and detailed information of anticancer drugs approved in China and the United States were acquired. The annual number, time lag, and basic characteristics, including drug type, mechanism, enterprise type, indication population, drug target, and cancer type of approved drugs were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty-seven and 118 new anticancer drugs were approved in China and the US, respectively, showing a stable trend in the US, while a significant increase was observed after 2016 in China. Of the 42 cancer medicines launched in both countries, the US took precedence, and the median time lag markedly decreased, from 6.53 years in 2012 to 0.88 years in 2020. A total of 14.4% of drugs were applicable to children in the US, while only 2.3% were applicable in China, and there was no difference in drug type and enterprise. Thirty-one and 43 targets were explored, with respect to 27 and 36 cancer types in China and the US, respectively, during the period. In addition, the expenditure of drugs on PD-1 and PD-L1 in China was generally lower than that in America.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The availability of new anticancer drugs has increased dramatically in the past decade, particularly in China. Compared with the US, the launch of new anticancer drugs in China lags behind, but the time lag has been shortened significantly, and better affordability is observed in immune drugs. More attention should be given to differentiated innovation, and unmet medical needs in special populations like childhood tumors, which are important directions of new drug R&amp;amp;D in China.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.930846","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T15:54:47Z","timestamp":1658505287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States"],"prefix":"10.3389","volume":"12","author":[{"given":"Huiyao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12197","article-title":"Cancer Incidence, Mortality, and Burden in China: A Time-Trend Analysis and Comparison With the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30090-1","article-title":"Cancer-Related Productivity Losses in BRICS Countries","volume":"19","author":"Venkatesan","year":"2018","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30073-5","article-title":"Cancer Registration in China and its Role in Cancer Prevention and Control","volume":"21","author":"Wei","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12025","article-title":"Cancer Burden of Major Cancers in China: A Need for Sustainable Actions","volume":"40","author":"Cao","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21597","article-title":"Enhancing Global Access to Cancer Medicines","volume":"70","author":"Cortes","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0313-2","article-title":"New Drug Approvals in Oncology","volume":"17","author":"Kurzrock","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of Expedited Programmes for Cancer Drug Approval in China","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw213","article-title":"ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe","volume":"27","author":"Cherny","year":"2016","journal-title":"Ann Onco"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx521","article-title":"International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Onco"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer Statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer Statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B13","unstructured":"NextPharma Database2021"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044543","article-title":"Platform Study of Genotyping-Guided Precision Medicine for Rare Solid Tumours: A Study Protocol for a Phase II, Nonrandomized, 18-Month, Open-Label, Multiarm, Single-Centre Clinical Trial Testing the Safety and Efficacy of Multiple Chinese-Approved Targeted Drugs and PD-1 Inhibitors in the Treatment of Metastatic Rare Tumours","volume":"11","author":"Wang","year":"2021","journal-title":"BMJ Open"},{"key":"B15","unstructured":"Watson HealthIBM\n          IBM Micromedex RED BOOK Database2021"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30491-7","article-title":"Changes in Clinical Trials of Cancer Drugs in Mainland China Over the Decade 2009-18: A Systematic Review","volume":"20","author":"Li","year":"2019","journal-title":"Lancet Oncol"},{"key":"B17","first-page":"696","article-title":"The 60-Year Development History and Main Achievements of Clinical Trials of New Antitumour Drugs in China (1960-2020)","volume":"43","author":"Shi","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B18","unstructured":"Guidance for Clinical Research and Development of Antitumor Drugs Oriented by Clinical Value2021"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.12.021","article-title":"An Overview of Cancer Drugs Approved Through Expedited Approval Programs and Orphan Medicine Designation Globally Between 2011 and 2020","volume":"27","author":"Wang","year":"2022","journal-title":"Drug Discov Today"},{"key":"B20","unstructured":"Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics2014"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing Cytokines and Chemokines for Cancer Therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00159-8","article-title":"The Nobel Prize-Winning Path From Oxygen Sensing Research to New Drugs","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.044","article-title":"Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients","volume":"183","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2021.08.002","article-title":"Advances on Anticancer New Drugs in China and the USA in 2020: From Ongoing Trial to Drug Approval","volume":"1","author":"Huang","year":"2021","journal-title":"JNCC"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30329-6","article-title":"Clinical Development of Immuno-Oncology in China","volume":"21","author":"Wu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-022-01227-1","article-title":"The Global Landscape of Neoadjuvant and Adjuvant Anti-PD-1\/PD-L1 Clinical Trials","volume":"15","author":"Wu","year":"2022","journal-title":"J Haematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2116863","article-title":"The Wild West of Checkpoint Inhibitor Development","volume":"386","author":"Beaver","year":"2021","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00003-7","article-title":"Comparing Development Strategies for PD1\/PDL1-Based Immunotherapies","author":"Li","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0140-6736(18)31034-1","article-title":"Cancer Drugs in China: Affordability and Creativity","volume":"391","year":"2018","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9797","article-title":"United States Health Care Reform: Progress to Date and Next Steps","volume":"316","author":"Obama","year":"2016","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2019-002087","article-title":"Towards Universal Health Coverage: Achievements and Challenges of 10 Years of Health Care Reform in China","volume":"5","author":"Tao","year":"2020","journal-title":"BMJ Glob Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.930846\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T15:54:51Z","timestamp":1658505291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.930846\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":31,"alternative-id":["10.3389\/fonc.2022.930846"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.930846","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"article-number":"930846"}}